Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments.

Wu X, Qu D, Weygant N, Peng J, Houchen CW.

Cancers (Basel). 2020 Jan 22;12(2). pii: E274. doi: 10.3390/cancers12020274.

2.

DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers.

Sureban SM, Berahovich R, Zhou H, Xu S, Wu L, Ding K, May R, Qu D, Bannerman-Menson E, Golubovskaya V, Houchen CW.

Cancers (Basel). 2019 Dec 23;12(1). pii: E54. doi: 10.3390/cancers12010054.

3.

Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer.

Qu D, Weygant N, Yao J, Chandrakesan P, Berry WL, May R, Pitts K, Husain S, Lightfoot S, Li M, Wang TC, An G, Clendenin C, Stanger BZ, Houchen CW.

J Oncol. 2019 Aug 5;2019:6402925. doi: 10.1155/2019/6402925. eCollection 2019.

4.

Dclk1 in tuft cells promotes inflammation-driven epithelial restitution and mitigates chronic colitis.

Yi J, Bergstrom K, Fu J, Shan X, McDaniel JM, McGee S, Qu D, Houchen CW, Liu X, Xia L.

Cell Death Differ. 2019 Sep;26(9):1656-1669. doi: 10.1038/s41418-018-0237-x. Epub 2018 Nov 26.

PMID:
30478383
5.

Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.

Ge Y, Weygant N, Qu D, May R, Berry WL, Yao J, Chandrakesan P, Zheng W, Zhao L, Zhao KL, Drake M, Vega KJ, Bronze MS, Tomasek JJ, An G, Houchen CW.

Int J Cancer. 2018 Sep 1;143(5):1162-1175. doi: 10.1002/ijc.31400. Epub 2018 Apr 16.

6.

Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.

Chandrakesan P, Yao J, Qu D, May R, Weygant N, Ge Y, Ali N, Sureban SM, Gude M, Vega K, Bannerman-Menson E, Xia L, Bronze M, An G, Houchen CW.

Mol Cancer. 2017 Feb 1;16(1):30. doi: 10.1186/s12943-017-0594-y.

7.

Intestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injury.

Chandrakesan P, May R, Weygant N, Qu D, Berry WL, Sureban SM, Ali N, Rao C, Huycke M, Bronze MS, Houchen CW.

Sci Rep. 2016 Nov 23;6:37667. doi: 10.1038/srep37667.

8.

(Z)-3,5,4'-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression.

Nguyen CB, Kotturi H, Waris G, Mohammed A, Chandrakesan P, May R, Sureban S, Weygant N, Qu D, Rao CV, Dhanasekaran DN, Bronze MS, Houchen CW, Ali N.

Cancer Res. 2016 Aug 15;76(16):4887-96. doi: 10.1158/0008-5472.CAN-15-2722. Epub 2016 Jun 10.

9.

Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase.

Weygant N, Ge Y, Qu D, Kaddis JS, Berry WL, May R, Chandrakesan P, Bannerman-Menson E, Vega KJ, Tomasek JJ, Bronze MS, An G, Houchen CW.

Cancer Res. 2016 Jul 15;76(14):4090-9. doi: 10.1158/0008-5472.CAN-16-0029. Epub 2016 Jun 10.

10.

Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.

Sureban SM, Madhoun MF, May R, Qu D, Ali N, Fazili J, Weygant N, Chandrakesan P, Ding K, Lightfoot SA, Houchen CW.

Oncotarget. 2015 Nov 10;6(35):37200-15. doi: 10.18632/oncotarget.5808.

11.

Regulation of miRNAs by agents targeting the tumor stem cell markers DCLK1, MSI1, LGR5, and BMI1.

Sureban SM, Qu D, Houchen CW.

Curr Pharmacol Rep. 2015 Aug 1;1(4):217-222.

12.

Dclk1+ small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal.

Chandrakesan P, May R, Qu D, Weygant N, Taylor VE, Li JD, Ali N, Sureban SM, Qante M, Wang TC, Bronze MS, Houchen CW.

Oncotarget. 2015 Oct 13;6(31):30876-86. doi: 10.18632/oncotarget.5129.

13.

Ablation of Doublecortin-Like Kinase 1 in the Colonic Epithelium Exacerbates Dextran Sulfate Sodium-Induced Colitis.

Qu D, Weygant N, May R, Chandrakesan P, Madhoun M, Ali N, Sureban SM, An G, Schlosser MJ, Houchen CW.

PLoS One. 2015 Aug 18;10(8):e0134212. doi: 10.1371/journal.pone.0134212. eCollection 2015.

14.

Dietary Pectin Increases Intestinal Crypt Stem Cell Survival following Radiation Injury.

Sureban SM, May R, Qu D, Chandrakesan P, Weygant N, Ali N, Lightfoot SA, Ding K, Umar S, Schlosser MJ, Houchen CW.

PLoS One. 2015 Aug 13;10(8):e0135561. doi: 10.1371/journal.pone.0135561. eCollection 2015.

15.

Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases.

Ali N, Chandrakesan P, Nguyen CB, Husain S, Gillaspy AF, Huycke M, Berry WL, May R, Qu D, Weygant N, Sureban SM, Bronze MS, Dhanasekaran DN, Houchen CW.

Oncotarget. 2015 Aug 21;6(24):20327-44.

16.

Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells.

Qu D, Johnson J, Chandrakesan P, Weygant N, May R, Aiello N, Rhim A, Zhao L, Zheng W, Lightfoot S, Pant S, Irvan J, Postier R, Hocker J, Hanas JS, Ali N, Sureban SM, An G, Schlosser MJ, Stanger B, Houchen CW.

PLoS One. 2015 Feb 27;10(2):e0118933. doi: 10.1371/journal.pone.0118933. eCollection 2015.

17.

DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.

Weygant N, Qu D, May R, Tierney RM, Berry WL, Zhao L, Agarwal S, Chandrakesan P, Chinthalapally HR, Murphy NT, Li JD, Sureban SM, Schlosser MJ, Tomasek JJ, Houchen CW.

Oncotarget. 2015 Feb 10;6(4):2193-205.

18.

DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.

Whorton J, Sureban SM, May R, Qu D, Lightfoot SA, Madhoun M, Johnson M, Tierney WM, Maple JT, Vega KJ, Houchen CW.

Dig Dis Sci. 2015 Feb;60(2):509-13. doi: 10.1007/s10620-014-3347-4. Epub 2014 Oct 5.

PMID:
25283374
19.

DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition.

Chandrakesan P, Weygant N, May R, Qu D, Chinthalapally HR, Sureban SM, Ali N, Lightfoot SA, Umar S, Houchen CW.

Oncotarget. 2014 Oct 15;5(19):9269-80.

20.

Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.

Weygant N, Qu D, Berry WL, May R, Chandrakesan P, Owen DB, Sureban SM, Ali N, Janknecht R, Houchen CW.

Mol Cancer. 2014 May 6;13:103. doi: 10.1186/1476-4598-13-103.

Supplemental Content

Loading ...
Support Center